Netupitant is an antiemetic agent used in combination with palonosetron to prevent acute and delayed vomiting and nausea caused by chemotherapy. Netupitant is a neurokinin 1 receptor antagonist.
- Mechanism
- Curator reviewed
Delayed emesis (vomiting) has been largely associated with the activation of tachykinin family neurokinin 1 (NK1) receptors (broadly distributed in the central and peripheral nervous systems) by substance P. As shown in in vitro and in vivo studies, netupitant inhibits substance P mediated responses.
- Primary indication
- Netupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy including highly emetogenic...Curator reviewed · 2 structured indications
- Formula / weight
- C30H32F6N4O · 578.603 g/mol (avg)
- First approval
- Canada, 2022 · United States, 2014 · European Union, 2016
- Code names
- RO 67-3189/000
- Brand names
Resolves to
Clinical / RWD
Structure
InChIKey
WAXQNWCZJDTGBU-UHFFFAOYSA-NSMILESCN(C(=O)C(C)(C)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CN=C(C=C1C1=CC=CC=C1C)N1CCN(C)CC1Targets
Transporters
What you can answer from here — as of June 15, 2026
1Protein targetEach mapped to UniProt, with action and pharmacological actionListed above
1TransporterSubstrate / inhibitor direction, not just membershipListed above
Which drugs share a target with Netupitant, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account